Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 5/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14306761 | 0.88 | METAP1 (0.72) | METAP1ACHECYP19A1CYP27A1CYP24A1 | |
| SCHEMBL8028034 | 0.85 | METAP1 (0.64) | METAP1ACHECYP19A1CYP27A1CYP24A1 | |
| SCHEMBL8598724 | 0.84 | METAP1 (0.69) | METAP1ACHECYP19A1HTR2AHTR2C | |
| SCHEMBL8874562 | 0.84 | METAP1 (0.69) | METAP1ACHECYP19A1HTR2AHTR2C | |
| SCHEMBL8600912 | 0.82 | METAP1 (0.64) | METAP1ACHECYP19A1CYP24A1 | |
| SCHEMBL8873898 | 0.82 | METAP1 (0.64) | METAP1ACHECYP19A1CYP24A1 | |
| SCHEMBL8601454 | 0.81 | METAP1 (0.62) | METAP1ACHECYP19A1HTR2AHTR2C | |
| SCHEMBL30667087 | 0.81 | CYP19A1 (0.62) | METAP1ACHECYP19A1CYP24A1 | |
| SCHEMBL8601453 | 0.81 | METAP1 (0.62) | METAP1ACHECYP19A1HTR2AHTR2C | |
| SCHEMBL7784427 | 0.81 | CYP19A1 (0.62) | METAP1ACHECYP19A1CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | METAP1 3112/4885ACHE 2442/4885CYP19A1 1319/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | METAP1 3112/4885ACHE 2442/4885CYP19A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.